Home › Research › Drug development
Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody
Zhang H, Zhu X, Pascual G, Wadia JS, Keogh E, Hoozemans JJ, Siregar B, Inganäs H et al.. Structure (London, England : 1993), 2018-10-11
Topic: Brain proteins, microglia and lab models
Aggregation of the hyperphosphorylated protein tau into neurofibrillary tangles and neuropil threads is a hallmark of Alzheimer disease (AD). Identification and characterization of the epitopes recognized by anti-tau antibodies might shed light on the molecular mechanisms of AD pathogenesis. Here we report on the biochemical and structural characterization of a tau-specific monoclonal antibody CBTAU-24.1, which was isolated from the human memory B cell repertoire.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, H., Zhu, X., Pascual, G., Wadia, J. S., Keogh, E., Hoozemans, J. J., et al. (2018). Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody. Structure (London, England : 1993). https://doi.org/10.1016/j.str.2018.08.012
Vancouver
Zhang H, Zhu X, Pascual G, Wadia JS, Keogh E, Hoozemans JJ, et al. Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody. Structure (London, England : 1993). 2018. doi:10.1016/j.str.2018.08.012. PMID: 30318466.
BibTeX
@article{zhang2018-30318466,
author = {Zhang, H. and Zhu, X. and Pascual, G. and Wadia, J. S. and Keogh, E. and Hoozemans, J. J. and Siregar, B. and Inganäs, H. and others},
title = {{Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody}},
journal = {Structure (London, England : 1993)},
year = {2018},
doi = {10.1016/j.str.2018.08.012},
pmid = {30318466},
url = {https://doi.org/10.1016/j.str.2018.08.012}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Identification and characterization of the epitopes recognized by anti-tau antibodies might shed light on the molecular mechanisms of AD pathogenesis.
- Here we report on the biochemical and structural characterization of a tau-specific monoclonal antibody CBTAU-24.1, which was isolated from the human memory B cell repertoire.
- Immunohistochemical staining with CBTAU-24.1 specifically detects pathological tau structures in AD brain samples.
- The crystal structure of CBTAU-24.1 Fab with a phosphorylated tau peptide revealed recognition of a unique epitope (Ser235-Leu243) in the tau proline-rich domain.
Why it matters
This study characterized a tau-specific monoclonal antibody, CBTAU-24.1, isolated from the human memory B cell repertoire, and reported its crystal structure with a phospho-tau epitope. The work is laboratory-based and aims to shed light on molecular mechanisms of Alzheimer's disease pathogenesis, not to demonstrate a treatment.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Structure (London, England : 1993)) |
| Journal's citation record | 2 / 4 | Structure: journal h-index 237 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 2 / 6 | Cited 1.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Ian A. Wilson: h-index 176 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30318466) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.